Obesity care coverage tends to focus on a narrow set of moments. A new drug’s approval. A celebrity’s weight loss. A debate about insurance coverage.
Those are real stories. However, they miss the larger one underneath them, which is what obesity treatment actually prevents when it works.
Obesity is a documented risk factor for type 2 diabetes, heart disease, certain cancers, and a long list of other conditions that develop gradually over years, often without a single dramatic moment that makes for an easy headline.
Myra Ahmad, the founder and CEO of Mochi Health, has argued that this is exactly the wrong way to think about the category.
Obesity care is not primarily a story about appearance, willpower, or even a single medication.
It is a story about the years of healthy life a patient gets to keep by addressing the disease early enough to prevent the complications that would otherwise follow.
Prevention is a difficult story to tell well. A patient who begins treatment for obesity in their thirties and never develops type 2 diabetes as a result does not generate a dramatic before-and-after moment.
That invisibility is precisely why prevention gets less cultural attention than acute treatment, even when its impact on a person’s life is larger.
Ahmad has described the human stakes of this in direct terms: “It’s the years of life we have saved from these treatments by preventing obesity related comorbidities like heart attacks, strokes, and diabetes.”
That framing treats the measure of success not as pounds lost but as disease that never had to be treated at all, a standard that is harder to market but arguably more meaningful to the patient living it.
The clinical logic behind this argument is straightforward. Obesity, left untreated, tends to compound over time, contributing to conditions that become progressively more serious and more expensive to treat as they advance.
Addressing the underlying disease earlier interrupts that progression before it reaches the point of a cardiac event, a diabetes diagnosis, or another complication that could have been avoided.
That is a fundamentally different way of measuring success than the one most obesity care coverage defaults to. Ahmad’s framing asks a different question entirely: not how much weight did a patient lose, but how much disease did they avoid, and how many years of healthy life did that avoidance actually buy them.
Those are related outcomes, but they are not the same outcome, and conflating them understates what treating obesity seriously can actually accomplish for a patient’s long-term health.
Part of why preventive obesity care struggles for attention is that the broader culture has spent decades treating obesity primarily as an appearance issue rather than a disease with measurable downstream consequences.
That framing shapes how insurers evaluate coverage, how media covers new treatments, and even how patients themselves talk about why they are seeking care.
A patient who describes their own treatment in terms of appearance rather than long-term health risk is, in a sense, absorbing the same cultural framing that has made prevention such a hard story to tell in the first place.
Shifting that framing matters beyond individual patient experience.
A culture that treats obesity as a cosmetic concern is less likely to fund research into its downstream complications. It’s less likely to train providers to treat it as seriously as other chronic diseases. Possibly most importantly, it is less likely to build healthcare infrastructure, like the physician-guided, longitudinal care Mochi Health has built its platform around, that treats obesity with the same seriousness given to any other major chronic disease.
The current wave of attention on obesity treatment has been driven largely by a handful of high-profile medications. That attention has been valuable for reducing stigma and expanding access.
But a story focused only on the drugs themselves misses the more consequential story about what happens to the millions of patients using those treatments over the following decades, whether they actually avoid the comorbidities that untreated obesity would have produced, and whether the healthcare system is built to support that kind of long-term prevention rather than a single prescription handed out and left unmanaged.
That longer story requires more than a medication. It requires a care structure built around monitoring a patient’s health over years, not months, catching early signs of the conditions obesity puts a patient at risk for, and adjusting treatment as a patient’s needs change over time.
Ahmad’s argument is built around physician and dietitian pairings that stay with a patient long term, treats the medication as one part of a much longer prevention story rather than the whole story itself.
Getting the preventive obesity care story right would mean measuring and reporting on outcomes that take years to materialize: rates of diabetes onset among treated patients, cardiovascular events avoided, the actual healthspan gained rather than just the weight lost in the first several months of treatment.
That is a much harder story to tell than a single dramatic transformation. It requires patience, longitudinal data, and a willingness to talk about outcomes that are defined by the absence of a bad event rather than the presence of a good one.
It is also the story that actually matters most to the patients living through it. A patient who avoids a heart attack because their obesity was treated early may never know exactly how much risk they escaped. The years of healthy life that avoidance produces are real regardless of whether anyone ever writes a headline about them.
That is the story preventive obesity care deserves, even if it is a harder one to tell than the story the culture has settled for instead.
Sources: Mochi Health RFI Intake document (Myra Ahmad quote on years of life saved and comorbidity prevention).
